البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
ALFUZOSIN HYDROCHLORIDE
PRO DOC LIMITEE
G04CA01
ALFUZOSIN
10MG
TABLET (EXTENDED-RELEASE)
ALFUZOSIN HYDROCHLORIDE 10MG
ORAL
100
Prescription
Selective Alfa-1-Adrenergic Blocking Agents
Active ingredient group (AIG) number: 0146806001; AHFS:
CANCELLED POST MARKET
2018-11-30
_Alfuzosin _ _Page 1 of 38_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr ALFUZOSIN Alfuzosin Hydrochloride Prolonged-Release Tablets 10 mg Pharmaceutical standard: Professed SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION (AUR) ATC Code: G04CA01 PRO DOC LTÉE 2925, boul. Industriel Laval, Quebec H7L 3W9 Date of Revision: August 11, 2017 Submission Control No.: 208229 _Alfuzosin _ _Page 2 of 38_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................... 3 SUMMARY PRODUCT INFORMATION .............................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................... 3 CONTRAINDICATIONS ......................................................................................................... 3 WARNINGS AND PRECAUTIONS........................................................................................ 4 ADVERSE REACTIONS ......................................................................................................... 6 DRUG INTERACTIONS ........................................................................................................ 11 DOSAGE AND ADMINISTRATION .................................................................................... 13 OVERDOSAGE ...................................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY .................................................................. 14 STORAGE AND STABILITY................................................................................................ 19 SPECIAL HANDLING INSTRUCTIONS ............................................................................. 19 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................... 19 PART II: SCIENTIFIC INFORMATION ........................................... اقرأ الوثيقة كاملة